Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1PMR3)

Drug Name

Sterculic acid Drug Info

Synonyms

STERCULIC ACID; 738-87-4; Sterculinic acid; UNII-MXV06G5ROK; 9,10-methylene-9-octadecenoic acid; MXV06G5ROK; 2-octyl-1-cyclopropene-1-octanoic acid; 8-(2-octylcyclopropen-1-yl)octanoic acid; omega-(2-n-octylcycloprop-1-enyl)octanoic acid; Sterculinsaeure; ster-culic acid; Sterculia-Saeure; HSDB 3904; PubChem20404; 1-Cyclopropene-1-octanoic acid, 2-octyl-; FA(19:1)(cyclo); AC1L20NB; SCHEMBL31295; 55088-60-3; 2-Octyl-1-cyclopropene-1-octanoic acid homopolymer; CHEBI:9261; US8962837, Sterculic acid; CHEMBL3677268

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 12921
ChEBI ID: CHEBI:9261
CAS Number: CAS 738-87-4
TTD Drug ID: DM1PMR3

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Acyl-CoA desaturase (SCD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Isoxyl	DMJL10P	Bacterial infection	1A00-1C4Z	Approved	[2]
Aramchol	DMDLGRO	Lipid metabolism disorder	5C52.Z	Phase 2/3	[3]
MK-8245	DMG6KXB	Type-2 diabetes	5A11	Phase 2	[4]
ISIS 147919	DMTE3FJ	Discovery agent	N.A.	Investigative	[5]
2-(4-benzoylpiperazin-1-yl)thiazole-5-carboxamide	DMJA5Y4	Discovery agent	N.A.	Investigative	[6]
MF-152	DMBLUSA	Discovery agent	N.A.	Investigative	[7]
CVT-12012	DMOCKMZ	Diabetic complication	5A2Y	Investigative	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Acyl-CoA desaturase (SCD)	TT6RIOV	ACOD_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92.
3	The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014 Dec;12(12):2085-91.e1.
4	Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. J Med Chem. 2011 Jul 28;54(14):5082-96.
5	US patent application no. 7,132,529, Antisense modulation of stearoyl-CoA desaturase expression.
6	Thiazole analog as stearoyl-CoA desaturase 1 inhibitor. Bioorg Med Chem Lett. 2009 Sep 1;19(17):5214-7.
7	SAR and optimization of thiazole analogs as potent stearoyl-CoA desaturase inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1593-7.
8	Potent, orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4070-4.